{"disease":{"id":"mss-metastatic-colorectal-cancer","name":"mss metastatic colorectal cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06849362","title":"Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"Yue Gou","has_results":false},{"nct_id":"NCT07405736","title":"Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":124,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04046445","title":"Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":96,"lead_sponsor_name":"Amal Therapeutics","has_results":false},{"nct_id":"NCT07446322","title":"FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Oncolytics Biotech","has_results":false},{"nct_id":"NCT06549907","title":"A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT06613113","title":"Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Ningbo Medical Center Lihuili Hospital","has_results":false},{"nct_id":"NCT05019534","title":"Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"West China Hospital","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}